Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details)

v3.26.1
Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details) - USD ($)
 3 Months Ended
Feb. 21, 2025
Mar. 31, 2026
Mar. 31, 2025
Research and development (excluding stock-based compensation) expense:      
PAH   $ 8,617,555 $ 9,330,844
Parkinson's disease [1]   0 142,420
Other research and development   430,895 587,128
Selling, general and administrative (excluding stock-based compensation)   3,607,057 3,660,282
Change in fair value contingent consideration $ (4,435,443) (373,354) (1,164,864)
Stock-based compensation expense   5,559,766 2,042,196
Total costs and expenses   17,841,919 14,598,006
Loss from operations   (17,841,919) (14,598,006)
Interest income   1,461,079 919,271
Net loss   (16,380,840) (13,678,735)
Operating Segment      
Research and development (excluding stock-based compensation) expense:      
Stock-based compensation expense   $ 5,559,766 $ 2,042,196
[1] The March 31, 2025 amount includes a one-time (non-cash) charge of $7.4 million for the acquired IPR&D related to the CorHepta acquisition.